> ## Content Index
> Fetch the complete content index at: https://chinapharmadesk.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Qilu registered a Phase 3 for its Claudin6 ADC. The trial has not started.
- URL: https://chinapharmadesk.com/qilu-qls5132-cldn6-adc-phase3/
- Published: 2026-11-12T11:59:00.000Z
- Updated: 2026-11-13T10:45:59.000Z
- Description: Qilu Pharmaceutical registered a 420-patient Phase 3 ovarian cancer trial (NCT07926048) for Claudin6 ADC QLS5132; ClinicalTrials.gov still lists the study as not yet recruiting.
- Author: Lin Yi
- Tags: Desk brief, Pipeline, Qilu Pharmaceutical, Oncology & ADC

Chinese industry notes on 12 November treated Qilu’s QLS5132 as a finished step: the first Claudin6 antibody-drug conjugate in the world to reach Phase 3\. The registry entry they are citing is a plan, not a started study.

ClinicalTrials.gov posted [NCT07926048](https://clinicaltrials.gov/study/NCT07926048?ref=chinapharmadesk.com) on 9 November. Qilu Pharmaceutical is the sponsor. The design is a randomized, open-label comparison of QLS5132 alone against the physician’s choice of liposomal doxorubicin, paclitaxel, or topotecan, in platinum-resistant recurrent ovarian, fallopian-tube, or primary peritoneal cancer. Enrollment is set at 420\. Progression-free survival and overall survival are both primary endpoints. The posted start date is December 2026\. The status, as of the 9 November posting, is not yet recruiting, and the record lists no countries and no sites.

That is still a lead on the obvious rival. TORL Bio’s TORL-1-23 had looked like the faster Claudin6 ADC; its pivotal study in this setting, CATALINA-2, is a Phase 2, with topline results talked about for mid-2027\. An ESMO-GI update put TORL-1-23’s response rate near 32% in an evaluable ovarian cohort. Qilu is ahead on the phase number. It is not ahead on patients treated in a registration study.

The response rate that will get copied into slides is older and smaller. At AACR in April, Qilu reported a Phase 1 cut in platinum-resistant ovarian cancer: 28 patients treated, 18 evaluable, a 50% response rate and 94% disease control; at 3.2 mg/kg and above, 17 patients showed a 52.9% response rate. That is a dose-finding poster. It is the wrong denominator for a 420-patient survival trial that has not opened a site.

For anyone looking at China ADC rights, the sentence to keep is the unglamorous one. Qilu is first to register a Claudin6 Phase 3\. It will be first to run one only when a patient is dosed.

*Related on China Pharma Desk:* [*TYK’s RMB 300m Huiyu settlement clearing Qilu’s TY-9591 China rights*](https://chinapharmadesk.com/tyk-ty9591-huiyu-qilu-settlement/)